Results of the study and of 5 years follow up of depressed patients who participated in the study during 2014-2015. We will locate the participants and will interview them will use the same questionnaires to evaluate their depressive symptoms. We will also measure the time to relapse.
Prospective observational follow-up of participants from a prior ketamine study (n≈16) assessing depressive symptoms with MADRS, plus CGI-S and CGI-I at acute timepoints; primary outcome includes time to relapse.
Anamnestic data and standardised questionnaires will be collected; sample is a non-probability prospective cohort drawn from prior study participants. Site: Revital Amiaz (Ramat Gan, Israel).
No exclusion criteria listed.